PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
BNGO vs. PFE
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between BNGO and PFE is 0.12, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

BNGO vs. PFE - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bionano Genomics, Inc. (BNGO) and Pfizer Inc. (PFE). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-82.67%
-7.48%
BNGO
PFE

Key characteristics

Sharpe Ratio

BNGO:

-0.92

PFE:

-0.02

Sortino Ratio

BNGO:

-2.85

PFE:

0.15

Omega Ratio

BNGO:

0.69

PFE:

1.02

Calmar Ratio

BNGO:

-0.93

PFE:

-0.01

Martin Ratio

BNGO:

-1.50

PFE:

-0.04

Ulcer Index

BNGO:

61.78%

PFE:

9.64%

Daily Std Dev

BNGO:

100.59%

PFE:

23.17%

Max Drawdown

BNGO:

-99.95%

PFE:

-54.82%

Current Drawdown

BNGO:

-99.94%

PFE:

-50.77%

Fundamentals

Market Cap

BNGO:

$12.91M

PFE:

$146.72B

EPS

BNGO:

-$138.00

PFE:

$1.41

Total Revenue (TTM)

BNGO:

$22.61M

PFE:

$63.63B

Gross Profit (TTM)

BNGO:

-$3.04M

PFE:

$41.72B

EBITDA (TTM)

BNGO:

-$84.87M

PFE:

$16.34B

Returns By Period

In the year-to-date period, BNGO achieves a -69.02% return, which is significantly lower than PFE's -0.76% return.


BNGO

YTD

-69.02%

1M

-51.84%

6M

-83.01%

1Y

-92.30%

5Y*

-61.97%

10Y*

N/A

PFE

YTD

-0.76%

1M

-1.17%

6M

-7.10%

1Y

-0.53%

5Y*

-0.94%

10Y*

1.75%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

BNGO vs. PFE — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BNGO
The Risk-Adjusted Performance Rank of BNGO is 33
Overall Rank
The Sharpe Ratio Rank of BNGO is 55
Sharpe Ratio Rank
The Sortino Ratio Rank of BNGO is 00
Sortino Ratio Rank
The Omega Ratio Rank of BNGO is 11
Omega Ratio Rank
The Calmar Ratio Rank of BNGO is 22
Calmar Ratio Rank
The Martin Ratio Rank of BNGO is 55
Martin Ratio Rank

PFE
The Risk-Adjusted Performance Rank of PFE is 4141
Overall Rank
The Sharpe Ratio Rank of PFE is 4545
Sharpe Ratio Rank
The Sortino Ratio Rank of PFE is 3636
Sortino Ratio Rank
The Omega Ratio Rank of PFE is 3535
Omega Ratio Rank
The Calmar Ratio Rank of PFE is 4545
Calmar Ratio Rank
The Martin Ratio Rank of PFE is 4545
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

BNGO vs. PFE - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Bionano Genomics, Inc. (BNGO) and Pfizer Inc. (PFE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for BNGO, currently valued at -0.92, compared to the broader market-2.000.002.00-0.92-0.01
The chart of Sortino ratio for BNGO, currently valued at -2.85, compared to the broader market-4.00-2.000.002.004.006.00-2.850.16
The chart of Omega ratio for BNGO, currently valued at 0.69, compared to the broader market0.501.001.502.000.691.02
The chart of Calmar ratio for BNGO, currently valued at -0.93, compared to the broader market0.002.004.006.00-0.93-0.00
The chart of Martin ratio for BNGO, currently valued at -1.50, compared to the broader market-10.000.0010.0020.0030.00-1.50-0.02
BNGO
PFE

The current BNGO Sharpe Ratio is -0.92, which is lower than the PFE Sharpe Ratio of -0.02. The chart below compares the historical Sharpe Ratios of BNGO and PFE, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.00SeptemberOctoberNovemberDecember2025February
-0.92
-0.01
BNGO
PFE

Dividends

BNGO vs. PFE - Dividend Comparison

BNGO has not paid dividends to shareholders, while PFE's dividend yield for the trailing twelve months is around 6.53%.


TTM20242023202220212020201920182017201620152014
BNGO
Bionano Genomics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
PFE
Pfizer Inc.
6.53%6.33%5.70%3.12%2.64%3.92%3.68%3.12%3.54%3.70%3.48%3.34%

Drawdowns

BNGO vs. PFE - Drawdown Comparison

The maximum BNGO drawdown since its inception was -99.95%, which is greater than PFE's maximum drawdown of -54.82%. Use the drawdown chart below to compare losses from any high point for BNGO and PFE. For additional features, visit the drawdowns tool.


-100.00%-90.00%-80.00%-70.00%-60.00%-50.00%-40.00%SeptemberOctoberNovemberDecember2025February
-99.94%
-50.77%
BNGO
PFE

Volatility

BNGO vs. PFE - Volatility Comparison

Bionano Genomics, Inc. (BNGO) has a higher volatility of 48.20% compared to Pfizer Inc. (PFE) at 5.85%. This indicates that BNGO's price experiences larger fluctuations and is considered to be riskier than PFE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%SeptemberOctoberNovemberDecember2025February
48.20%
5.85%
BNGO
PFE

Financials

BNGO vs. PFE - Financials Comparison

This section allows you to compare key financial metrics between Bionano Genomics, Inc. and Pfizer Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab